BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...hematological cancer programs that hit IKAROS and AIOLOS...
...through more potent degradation of IKAROS and AIOLOS...
...lab are sold by Promega Corp.TARGETSAIOLOS (IKZF3) – IKAROS family zinc finger 3 BCR-ABL...
BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

...contributed to this report. TARGETSIL-38 – Interleukin-38IKZF1 (IKAROS; LYF1) - IKAROS family zinc finger 1IKZF3 (AIOLOS...
BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

...structures that thalidomide and other “imids” use as toeholds to bind the zinc-finger transcription factors AIOLOS...
...Investors: Versant, New Enterprise Associates CEO: Markus Warmuth Patents: None issued Targets AIOLOS (IKZF3) - IKAROS family zinc finger 3...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BioCentury | Dec 30, 2016
Company News

Clinical Genomics sales and marketing update

Clinical Genomics launched its Colvera blood-based test in the U.S. to monitor the recurrence of colorectal cancer. Colvera is a PCR-based test that measures two epigenetically modified genes -- hyper-methylated cytosolic branched chain amino-acid transaminase...
BioCentury | Aug 4, 2016
Targets & Mechanisms

Cereblon ambition

...its analogs - known as imids - act by trapping the transcription factors IKAROS and AIOLOS...
...Dundee, U.K. Yale University, New Haven, Conn. Targets and Compounds AIOLOS ( IKZF3 ) - IKAROS family zinc finger 3...
BioCentury | Mar 24, 2016
Financial News

Diagnostics play Clinical Genomics raises $15M

Clinical Genomics Pty. Ltd. (North Ryde, Australia) closed a $15 million series A round led by Australian venture firm OneVentures. This year, Clinical Genomics plans to launch its Gemini test in the U.S. for post-surgical...
BioCentury | Feb 1, 2016
Clinical News

2-Gene Colorectal Cancer Recurrence Test: Clinical trial data

An analysis of 120 patients with known colorectal recurrence status following resection of a primary tumor showed that Clinical Genomics’ 2-Gene Colorectal Cancer Recurrence Test had an overall sensitivity of 63% and specificity of 86%...
BioCentury | Jan 16, 2014
Distillery Therapeutics

Indication: Cancer

...finger 1 (IKZF1; LYF1); IKZF3; cereblon (CRBN) In vitro studies identified degradation of IKZF1 and IKZF3...
...of the CRBN ubiquitin ligase and promoted CRBN binding to the transcription factors IKZF1 and IKZF3...
BioCentury | Oct 15, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) IKAROS family zinc finger 1 (IKZF1) Genetic association studies suggest that deletions in IKZF1 could be used as a prognostic marker...
Items per page:
1 - 10 of 10